@article{934af230825d466681e10c2a21177cf6,
title = "CDAI and DAS28 in the management of rheumatoid arthritis in clinical practice",
keywords = "DAS28, disease activity, rheumatoid arthritis",
author = "Satoshi Takanashi and Yuko Kaneko and Tsutomu Takeuchi",
note = "Funding Information: Competing interests YK has received grants or speaking fees from AbbVie, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Hisamitsu, Jansen, Kissei, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi and UCB. TT has received research grants or speaking fees from Astellas Pharma, Bristol–Myers K.K., Chugai Pharmaceutical, Daiichi Sankyo, Takeda Pharmaceutical, Teijin Pharma, AbbVie GK, Asahikasei Pharma Corp., Mitsubishi Tanabe Pharma, Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., Abbivie GK, Nipponkayaku, Janssen, Pharmaceutical K.K., Taiho Pharmaceutical and Pfizer Japan.",
year = "2020",
month = may,
day = "1",
doi = "10.1136/annrheumdis-2019-216607",
language = "English",
volume = "79",
pages = "671--674",
journal = "Annals of the rheumatic diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "5",
}